✦ LIBER ✦

Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

✍ Scribed by Pengxiang Li; Marissa A. Blum; Joan Von Feldt; Sean Hennessy; Jalpa A. Doshi

Book ID: 111755976
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 133 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2010.00764.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CM1 ADHERENCE, DISCONTINUATION, AND SWIT

CM1 ADHERENCE, DISCONTINUATION, AND SWITCHING OF BIOLOGIC THERAPIES IN MEDICAID ENROLLEES WITH RHEUMATOID ARTHRITIS

✍ P Li; MA Blum; JMV Feldt; S Hennessy; JA Doshi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET C

PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

✍ M Gleeson; S Curkendall; V Patel; R Smith; M Zagari 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PMS63 SATISFACTION, PREFERENCE AND REASO

PMS63 SATISFACTION, PREFERENCE AND REASONS FOR BIOLOGIC TREATMENT DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

✍ N. Tandon; S. Bolge; K. Annunziata 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Systemic bone effects of biologic therap

Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis

✍ C. B. Confavreux; R. D. Chapurlat 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 776 KB

Pharmacoeconomic Aspects of the First-Li

Pharmacoeconomic Aspects of the First-Line Biologic Therapies in Russian Patients with Rheumatoid Arthritis

✍ Ryazhenov, V.V.; Gorokhova, S.G.; Emchenko, I.V. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Compliance with biologic therapies for r

Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?

✍ Curkendall, S. ;Patel, V. ;Gleeson, M. ;Campbell, R. S. ;Zagari, M. ;Dubois, R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Abstract ## Objective To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA). ## Methods An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was s